ArticleScientific reports2025
Neutrophil-mediated degradation of type III collagen is elevated in inflammatory bowel disease and DSS-induced colitis reflecting early mucosal damage.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory Bowel Disease (IBD) is characterized by mucosal injury in the gastrointestinal (GI) tract. During an abnormal immune response in the GI tract, excessive secretion of immune-cell proteases occurs. Neutrophils are the first responders, infiltrating into the inflamed interstitial matrix, where type III collagen accumulates. We aimed to develop a biomarker that reflects early inflammation before clinical symptoms arise; allowing us to intervene and prevent cumulative damage. A competitive enzyme-linked immunosorbent assay targeting a human neutrophil elastase degraded neo-epitope fragment of type III collagen (C3-HNE) was developed and assessed in serum samples from DSS-treated rats and a clinical cohort (n = 91, UC and CD). Moreover, C3M, an MMP- mediated type III collagen degradation marker, was tested for comparison. The DSS-treated rats had elevated C3-HNE levels on day 4, while C3M increased on days 10 and 14, compared to the non-DSS treated group. Percentage change analysis showed that C3-HNE rapidly peaked (day 1), while C3M displayed a sustained elevation over time. Serum C3-HNE concentrations increased in patients with IBD, including those in remission, compared to healthy donors, possibly indicating subclinical inflammation. This biomarker may reflect initial mucosal injury and could provide early detection of inflammation for patients in remission, monitoring flare episodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.